– UK, Slough – Indivior PLC (LON: INDV) / NASDAQ: INDV) announced the appointments of Dr. David Wheadon as Chair of the Board of Directors, of Daniel Ninivaggi as an Independent Non-Executive Director, and the appointment of Joe Ciaffoni as CEO.
Dr David Wheadon, Board Chair said, “Peter Bains, Jo LeCouilliard and Rob Schriesheim have been unswerving in their support of bringing needed therapeutic interventions to patients suffering from Opioid Use Disorder. I sincerely thank them for the service they have given to Indivior”.
About Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorders. Our vision is that all patients worldwide will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally, and its portfolio of products is available in over 30 countries worldwide.
For more: https://www.indivior.com/en
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.